During gait training in the parallel bars, the physical ther…
During gait training in the parallel bars, the physical therapist assistant used a mirror to help the patient correct their base of support, step-through gait pattern, and postural alignment as part of the treatment session. What is the therapist providing the patient with during and after the pt’s movement for corrective actions?
Read DetailsDuring a weekly rehab meeting, the physical therapist assist…
During a weekly rehab meeting, the physical therapist assistant (PTA) communicated with the supervising PT that the treatment session with Mr. Motivation was difficult. The session was unproductive due to the patient’s diminished arousal, delayed responses to 90% tactile/verbal cues, and lack of interest to stay engaged during bed mobility. The PTA provided constant redirection during the tx session to ensure pt safety due to confusion. What level of consciousness is the patient demonstrating?
Read DetailsMethotrexate is a disease-modifying antirheumatic drug (DMAR…
Methotrexate is a disease-modifying antirheumatic drug (DMARD) that is an antimetabolite chemotherapeutic agent. The drug is a folic acid antagonist that interferes with DNA synthesis and repair mechanisms. Tissues that are metabolically active are more sensitive to the effects of the medication. Serum levels peak at 1-2 hours after ingestion and 30-60 minutes after intramuscular injection. Prolonged effects of the medication can be seen in patients with ascites or other effusions since the medication accumulates in the third-space fluid. This drug is commonly used in the treatment of inflammatory arthritis, including rheumatoid arthritis and other autoimmune diseases. When methotrexate is used long-term, it has been associated with the development of elevations in liver aminotransferase levels, chronic liver injury, fibrosis of the liver, and cirrhosis. When administered in high intravenous doses, the drug may cause acute elevations of liver enzymes. Minor elevation of liver enzymes is common in patients who are taking methotrexate, but hepatotoxicity can occur. Liver aminotransferase levels and kidney function should be evaluated prior to starting therapy and monitored while taking the medication. Patients should be monitored for side effects, including stomatitis, gastrointestinal upset, alopecia, symptoms of myelosuppression, hepatotoxicity, and infection while taking methotrexate. In addition, patients should not become pregnant while taking methotrexate as this is a teratogenic and embryotoxic drug.
Read Details